About Incannex Healthcare Inc. - Common Stock (IXHL)
Incannex Healthcare Inc. is a biotechnology company focused on developing innovative therapies that harness the potential of cannabinoid-based medicine. The company is dedicated to conducting rigorous clinical research to create safe and effective treatments for a range of medical conditions, including pain, anxiety, and other illnesses. Incannex aims to navigate the evolving regulatory landscape and collaborate with medical professionals to bring cannabinoid solutions to patients, while also emphasizing the importance of scientific validation and patient safety in the pharmaceutical field. Read More
Scienjoy Holding Corporation (NASDAQ: SJ) is emerging as one of the most intriguing deep-value opportunities in global small-cap tech. Powered by a cash-rich, high-margin China livestreaming business and a bold expansion into Dubai’s fast-developing metaverse and AI economy, the company offers investors something rare: a profitable core plus a “free option” on one of the world’s most ambitious new digital markets . For investors seeking asymmetric upside, real operational discipline, and underappreciated catalysts, Scienjoy stands at a compelling inflection point.
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Specificity Inc. (OTCQB: SPTY), a next-generation ad tech company redefining precision digital marketing, announced it has signed a Letter of Intent (LOI) with Blackpearl Group (NZX: BPG) to build the world’s first fully integrated ad tech stack — a breakthrough designed to directly confront the estimated $250 billion in annual digital ad fraud that continues to drain the global advertising industry.
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts
The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
